Koren snapped up 500 million anti-thrombosis injections 4 products into the collection

Pharmaceutical Network February 7th, CDE official website shows that Hunan Colum Pharmaceutical's hydrochloric acid tiloffeban sodium chloride injection to copy 3 categories of applications for listing was accepted.
2019, sales of end-of-the-terminal erofeiban injections in China's public medical institutions reached nearly 500 million yuan, up 16.61 percent year-on-year, according to the company's internal network.
sodium chloride injection of roubles hydrochloride has 11 manufacturers such as Lunanbet Pharmaceuticals, Stone Pharmaceuticals Group Ombipu Pharmaceuticals, Yuanda Pharmaceuticals, Chengdu Bert Pharmaceuticals, etc.
the evaluation of the consistency, only Chengdu Bett Pharmaceuticals has applied for a supplementary evaluation.
trofiban is a non-peptide plateboard glycosin (GP) II.b/III.a subject antagonist, with a high degree of selectivity and specificity to plateplate II.b/III.a subjectivity, reversible inhibit plate plate aggregation, and short half-life, no antigen and few adverse reactions. according to
meters of intranet data, in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal injection sales have been close to 500 million yuan, up 16.61 percent year-on-year, the first half of 2020 slightly lower year-on-year, of which Lunanbet Pharmaceutical market share accounted for the largest, more than 40%, followed by Yuanda Pharmaceutical.
Source: Milnet consistent evaluation database hydrochloric acid terrabon sodium chloride injection has Lunanbet Pharmaceuticals, Stone Pharmaceutical Group Ombipu Pharmaceuticals, Sichuan Colum Pharmaceuticals, Yuanda Pharmaceuticals, Chengdu Bett Pharmaceuticals and other 11 manufacturers.
the evaluation of the consistency, only Chengdu Bett Pharmaceuticals has applied for a supplementary evaluation.
Sichuan Colum Pharmaceuticals, Lunanbet Pharmaceuticals, Yuanda Pharmaceuticals, Guizhou Jingfeng injections consistent evaluation of supplementary applications in the review and approval (in the drug review center);
3rd, the fourth batch of countries opened the tender.
night, Curran Pharmaceuticals announced that the company's Engele net tablets (10mg, 25mg), propofol medium/long chain fat emulsion (20ml:0.2g), injection of parsib sodium (20mg, 40mg), hydrochloric acid bromoso injection (2ml:15mg) to be selected according to the provincial market potential of the provinces.
The fourth batch of the proposed winning product situation note: the above-mentioned varieties of the proposed winning bid price and the number of proposed winning bid are based on the final data issued by the joint collection of Colum Pharmaceuticals said that the company's proposed winning bid of the Engli net tablets, propofol medium / long chain fat milk injection, In August 2020, November 2020 and December 2020, respectively, the hydrochloric acid bromotide injection was approved by the State Drug Administration for drug registration or drug supplement application, and sales revenue has not been obtained as of January 31, 2021.
2020 sales revenue of 498 million yuan using Parexib sodium (20mg, 40mg) for injections.
in the fourth batch of national procurement cycle, medical institutions will give priority to the use of selected drugs, and ensure the completion of the agreed procurement volume.
if the company subsequently signed a procurement contract and implementation, will further expand the sales of related products, improve market share, enhance the company's brand influence, the company's future operating performance has a positive impact.
sources: CDE official website, Mienet database, listed company announcement